RP

Royalty Pharma Sub-Manager, LLC

Concentrated strategySector-focusedMomentum follower

Total reported value

$172.8M

Reporting period: 2026-03-31 · Number of holdings: 4

Royalty Pharma Sub-Manager, LLC disclosed 4 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $172.8M and a quarterly turnover rate of 10.5%.

Personality snowflake

Concentration
100
Portfolio Stability
10.5
Momentum/Contrarian
100
Sector conviction
100
Diversification
8
Sizing Uniformity
96.1

Recent moves

  • Trim BHVN

    0.0%　-$8.3M

  • Add BCRX

    0.0%　$6.6M

  • Add CYTK

    0.0%　$2.3M

  • Add BCAX

    +89.1%　$823.4K

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1CYTKCytokinetics INCStock-Healthcare37.40%+1.04%—
2BCAXBicara Therapeutics INCStock-Other27.02%+0.25%+89.06%
3BCRXBiocryst Pharmaceuticals INCStock-Other21.19%+3.68%—
4BHVNBiohaven Ltd.Stock-Other14.38%-4.97%—

Holding changes this quarter

Royalty Pharma Sub-Manager, LLC's most significant position changes for 2026-03-31: Add: Bicara Therapeutics INC (BCAX) — shares +89.06%.

Position changes disclosed by Royalty Pharma Sub-Manager, LLC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1BCRXBiocryst Pharmaceuticals INC+3.7%—Unchanged
2CYTKCytokinetics INC+1%—Unchanged
3BCAXBicara Therapeutics INC+0.3%+89.06%Add
4BHVNBiohaven Ltd.-5%—Unchanged

FAQ

What is Royalty Pharma Sub-Manager, LLC and what type of investor is it?
Royalty Pharma Sub-Manager, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $172.8M, spread across 4 disclosed positions.
What are Royalty Pharma Sub-Manager, LLC's largest equity positions?
Based on the latest 13F filing, Royalty Pharma Sub-Manager, LLC's top holdings by market value are: 1. Cytokinetics INC (CYTK) — $64.6M (37.4%) 2. Bicara Therapeutics INC (BCAX) — $46.7M (27.0%) 3. Biocryst Pharmaceuticals INC (BCRX) — $36.6M (21.2%) 4. Biohaven Ltd. (BHVN) — $24.8M (14.4%)
What changes did Royalty Pharma Sub-Manager, LLC make in its most recent portfolio filing?
In the latest quarter, Royalty Pharma Sub-Manager, LLC was primarily adding exposure — initiating 0 new positions and adding to 1 existing holdings. The largest of these moves: Add: Bicara Therapeutics INC (BCAX) — shares +89.06%
What sectors does Royalty Pharma Sub-Manager, LLC focus on?
Royalty Pharma Sub-Manager, LLC is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%